GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC

CAR-T Digest - August 2020

23 December 2025: GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC

GSK Korea received regulatory approval from Korea’s Ministry of Food and Drug Safety for Blenrep (Belantamab mafodotin), marking the first approved ADC for multiple myeloma in the country
Blenrep is approved for adult patients with relapsed or refractory multiple myeloma as combination therapy with Bortezomib and Dexamethasone or Pomalidomide and Dexamethasone after more than one prior line of treatment
Approval is based on global Phase 3 trials DREAMM-7 and DREAMM-8, which demonstrated significant improvements in progression-free survival and overall survival versus standard daratumumab-based regimens
The drug targets BCMA and combines immune-mediated mechanisms with the cytotoxic payload mafodotin, which disrupts microtubules to kill tumor cells
Ophthalmic adverse events were observed but were largely manageable with dose adjustments, with low discontinuation rates (<9%), and efficacy was maintained even after modifying dosing schedules